Secure Survival Analysis

The Cox proportional hazards model is the workhorse of survival analysis, estimating the effect of covariates on the hazard rate. In a secure setting, the partial likelihood function is decomposed across parties using secret sharing. Each institution holds shares of its own data, and the iterative Newton-Raphson optimization for coefficient estimation is performed entirely on secret-shared values. The global model converges without any party seeing another's patient-level event times or censoring indicators.

The log-rank test is the standard non-parametric method for comparing survival distributions between two groups. In a multi-party setting, the test statistic is computed by securely aggregating observed and expected event counts across institutions at each distinct event time. Using secure aggregation protocols, the combined contingency tables are constructed without revealing individual strata counts, allowing researchers to test hypotheses like treatment efficacy across federated clinical trial data.

The Kaplan-Meier estimator generates the iconic step-function survival curve. Secure computation of this estimator requires parties to jointly compute the product-limit formula across all unique event times in the combined dataset. This involves securely sorting event times, counting at-risk individuals and events at each time point, and multiplying conditional survival probabilities. The resulting curve is revealed as the final output, while the underlying patient-level timelines remain private.

A defining challenge of survival analysis is right-censoring, where a subject's event time is unknown beyond a certain point. Secure protocols must correctly handle censoring indicators without leaking whether a specific individual was censored or experienced the event. Techniques involve representing each subject's data as a secret-shared tuple of (time, event indicator, covariates) and designing arithmetic circuits that conditionally include or exclude subjects from risk sets based on these encrypted flags.

Advanced survival models often require stratification by categorical variables or the incorporation of time-varying covariates. Secure protocols extend the basic Cox model by partitioning the computation into independent strata, each processed in parallel under MPC. For time-varying covariates, the counting process representation is used, where each subject contributes multiple observation intervals. Secure sorting and interval matching are performed obliviously to construct the correct risk sets at each event time.

Production-grade secure survival analysis is implemented in frameworks like MP-SPDZ and Crypten, which provide optimized building blocks for the required operations. Key optimizations include using Beaver triples for efficient secure multiplication in the Newton-Raphson steps and fixed-point arithmetic to approximate floating-point operations like exponentiation for the hazard function. These implementations enable collaborative pharmacovigilance studies and multi-center clinical trial analyses.

Pharmaceutical companies and hospital networks use secure Cox proportional hazards models to analyze treatment efficacy across distributed patient registries. Each institution holds private survival data—time to disease progression, censoring indicators, and treatment arms—and jointly computes hazard ratios without revealing individual records.

• Protocol: SPDZ-based MPC for arithmetic operations on secret-shared survival times
• Output: Global hazard ratio and confidence intervals, with no raw data exposure
• Real-world scale: Networks of 10–50 hospitals analyzing cohorts of 100,000+ patients
• Regulatory alignment: Satisfies GDPR and HIPAA data minimization requirements

Regulatory agencies and drug manufacturers perform secure Kaplan-Meier estimation to monitor adverse event timing across national pharmacovigilance databases. Each country's database contains proprietary patient timelines that cannot be exported due to sovereignty laws.

• Technique: Secret-shared survival curves computed via garbled circuit evaluation
• Key metric: Time-to-adverse-event across pooled populations
• Privacy guarantee: Each agency learns only the aggregated survival function, never individual event times
• Compliance: Enables joint analysis under conflicting jurisdictional privacy regimes

Competing insurance carriers collaborate on secure accelerated failure time models to refine mortality and lapse rate predictions. Each insurer contributes policyholder survival data—entry ages, event indicators, and covariate vectors—without revealing proprietary underwriting information.

• Model: Weibull AFT model implemented via oblivious transfer and Beaver triples
• Business value: Improved risk stratification while preserving competitive data moats
• Output: Shared baseline hazard function and covariate effect estimates
• Scale: Millions of policies analyzed across 5–10 participating carriers

Research consortia link genomic variants to time-to-event outcomes by securely joining genotype data from biobanks with clinical survival endpoints from hospital registries. Private set intersection identifies overlapping cohorts before secure Cox regression begins.

• Pipeline: PSI for cohort discovery → secret-shared covariate alignment → MPC-based Cox regression
• Application: Identifying genetic markers associated with cancer survival time
• Privacy: Neither party learns the other's non-overlapping records or individual-level data
• Frameworks: Implemented using MP-SPDZ and Crypten libraries

Medical device manufacturers and hospital systems jointly estimate cause-specific hazard functions when patients face multiple mutually exclusive failure events—such as death from cardiac causes versus stroke. Each institution's data contains sensitive competing event timelines.

• Method: Secure Fine-Gray subdistribution hazard models via arithmetic secret sharing
• Challenge: Handling complex censoring structures under cryptographic constraints
• Output: Cause-specific cumulative incidence functions without raw data pooling
• Use case: Comparing stent failure modes across implant registries

Drug sponsors and health systems collaborate on secure stratified Cox models to generate real-world evidence supporting label expansions. Each health system contributes electronic health record-derived survival endpoints while maintaining patient confidentiality.

• Stratification: Secure computation across demographic and clinical strata without revealing stratum membership
• Regulatory acceptance: FDA and EMA guidance supports privacy-preserving RWE methodologies
• Efficiency: Eliminates months of data use agreement negotiations
• Output: Stratum-specific hazard ratios with formal privacy guarantees